These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 9723300)

  • 41. Evaluation of tolerability, safety, and efficacy of cyclosporine microemulsion in renal transplant recipients.
    Gracida C; Melchor JL; Miranda ME; Bartolano C
    Transplant Proc; 1996 Aug; 28(4):2171-3. PubMed ID: 8769191
    [No Abstract]   [Full Text] [Related]  

  • 42. Neoral conversion in stable thoracic transplant patients leads to dose reduction.
    Zaldonis DB; Keenan RJ; Pham SM; Kormos RL; Griffith BP
    Transplant Proc; 1998 Aug; 30(5):1898-9. PubMed ID: 9723325
    [No Abstract]   [Full Text] [Related]  

  • 43. Induction therapy with bolus ATG increases cyclosporine sensitivity in renal transplant recipients.
    Varghese Z; Abudher MN; Fernando ON; Moorhead JF
    Transplant Proc; 2001 May; 33(3):2251-3. PubMed ID: 11377518
    [No Abstract]   [Full Text] [Related]  

  • 44. Clinical study of sandimmun neoral in cadaveric renal transplantation.
    Xue W; Chen Y; Xing J; Tian P
    Transplant Proc; 1996 Jun; 28(3):1333-4. PubMed ID: 8658682
    [No Abstract]   [Full Text] [Related]  

  • 45. Low incidence of acute cellular rejection in liver transplantation with Neoral.
    Imventarza O; Lendoire J; Bianco G; Saúl J; Braslavsky G; Trigo P; Cueto G; Duek F; Aziz H
    Transplant Proc; 1998 Aug; 30(5):1854. PubMed ID: 9723307
    [No Abstract]   [Full Text] [Related]  

  • 46. Monitoring of anti-rejection therapy by serum bile acids after liver transplantation.
    Klar E; Theilmann L; Hoffmann V; Hofmann W; Kraus T; Mehrabi A; Herfarth C
    Transplant Proc; 1998 Nov; 30(7):3567-9. PubMed ID: 9838562
    [No Abstract]   [Full Text] [Related]  

  • 47. Conventional versus Neoral cyclosporine in renal transplantation.
    Rovelli E; Bucci A; Maldifassi P; Belfiore A; D'Amico G
    Transplant Proc; 1998 Aug; 30(5):1764-5. PubMed ID: 9723272
    [No Abstract]   [Full Text] [Related]  

  • 48. Nephrotoxicity of FK 506 and cyclosporine when used as primary immunosuppression in liver transplant recipients.
    Porayko MK; Textor SC; Krom RA; Hay JE; Gores GJ; Wahlstrom HE; Sanchez-Urdazpal L; Richards T; Crotty P; Beaver S
    Transplant Proc; 1993 Feb; 25(1 Pt 1):665-8. PubMed ID: 7679835
    [No Abstract]   [Full Text] [Related]  

  • 49. Case studies: conversion from Sandimmune to Neoral in stable renal allograft recipients.
    Roth D; Miller J
    Transplant Proc; 1996 Aug; 28(4):2219-20; discussion 2218. PubMed ID: 8769204
    [No Abstract]   [Full Text] [Related]  

  • 50. Microemulsion cyclosporine (Neoral) immunosuppression for orthotopic liver transplantation in children reduces hospital stay.
    Arumugam R; Soriano HE; Scheimann AO; Reid BS; Gopalakrishna GS; Barakat O; Ozaki CF; Wood RP
    Transplant Proc; 1998 Aug; 30(5):1848-9. PubMed ID: 9723304
    [No Abstract]   [Full Text] [Related]  

  • 51. Potential role of Neoral in pediatric liver transplantation.
    Whitington PF; Alonso EM; Millis JM
    Transplant Proc; 1996 Aug; 28(4):2267-9. PubMed ID: 8769221
    [No Abstract]   [Full Text] [Related]  

  • 52. Growth acceleration on cyclosporine monotherapy after liver transplantation in children.
    Falkenstein K; Dunn S
    Transplant Proc; 1998 Aug; 30(5):1969-72. PubMed ID: 9723356
    [No Abstract]   [Full Text] [Related]  

  • 53. Use of cyclosporine MEPC (Neoral) in heart transplant recipients.
    Fukushima N; Ohtake S; Sawa Y; Nishimura M; Kobayashi Y; Shirakura R; Nakata S; Matsuda H
    Transplant Proc; 1998 Nov; 30(7):3337-8. PubMed ID: 9838473
    [No Abstract]   [Full Text] [Related]  

  • 54. Early use and oral absorption of cyclosporine neoral after liver transplantation.
    Kattner A; Ringe B; Haller GW; Kirchner G; Sewing KF; Winkler M
    Transplant Proc; 1998 Jun; 30(4):1422-3. PubMed ID: 9636576
    [No Abstract]   [Full Text] [Related]  

  • 55. Conversion from tacrolimus to Neoral in liver and kidney transplant recipients.
    Ott R; Bussenius-Kammerer M; Scholz D; Neuhaus R; Tolba RH; Fricke L; Müller V
    Transplant Proc; 2001; 33(7-8):3166-8. PubMed ID: 11750359
    [No Abstract]   [Full Text] [Related]  

  • 56. Preoperative induction therapy with oral cyclosporine for recipients of living-related renal transplants.
    Rudich SM; Bhaduri S; Chang T; Cahn J; Katznelson S; Perez RV
    Transplant Proc; 1998 Jun; 30(4):1339-42. PubMed ID: 9636545
    [No Abstract]   [Full Text] [Related]  

  • 57. Cyclosporine monotherapy in long-term pediatric liver transplant recipients.
    Martin SR; Paradis K; Alvarez F
    Transplant Proc; 1998 Jun; 30(4):1424-6. PubMed ID: 9636577
    [No Abstract]   [Full Text] [Related]  

  • 58. Comparison of cyclosporine monitoring with trough levels to levels obtained 6 hours after the morning dose in heart transplant patients: a prospective randomized study.
    Cantarovich M; Latter D; Fitchett D
    Transplant Proc; 1997; 29(1-2):602-4. PubMed ID: 9123149
    [No Abstract]   [Full Text] [Related]  

  • 59. Successful reconversion from tacrolimus to cyclosporine A Neoral in pediatric liver recipients.
    Melter M; Rodeck B; Kardorff R; Hoyer PF; Maibücher A; Brodehl J
    Transplant Proc; 1996 Aug; 28(4):2276-8. PubMed ID: 8769224
    [No Abstract]   [Full Text] [Related]  

  • 60. Cyclosporine A reduction and withdrawal in liver transplantation: a risk-benefit analysis.
    Golling M; Frankenberg MV; Hofmann WJ; Lohse A; Herfarth C; Otto G
    Transplant Proc; 1997 Nov; 29(7):2819-21. PubMed ID: 9365575
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.